Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. - Wikidata - awgldk - TriplyDB

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

http://www.wikidata.org/entity/Q38516135

about

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective Management of immunosuppressant agents following liver transplantation: Less is more Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).Drug interactions in HIV-infected patients treated for hepatitis C.Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.

P2860

Q26746910-F8640A1E-10ED-4100-8A64-491243C4BC45 Q26770033-2B6CCBC0-5DF9-470D-B82E-5C76FBC06952 Q30393824-D13770B9-EF7C-48E0-BB2C-97CFE417C41F Q36765588-66CBD047-C105-4B78-81E0-82B280A4DDBB Q37432877-99343672-7BB4-42CB-A26B-F3C26AE78558 Q40143109-B64DA8E7-A903-448B-ACDA-8A927B03E004 Q40604753-672EA6CA-F9CE-497F-A2A7-B023251FC4F3 Q42290798-40A8063C-4A65-43AC-BB83-02AA2AA0132E Q47571985-670428AB-A628-4B10-AB0F-D89575C06F59

P2860

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

http://www.wikidata.org/entity/Q38516135

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

@en

type

label

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

@en

prefLabel

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

@en

P1433

Q38516135-D3CDB6C9-E84D-4C7B-B09E-4E148B664299

P1476

Q38516135-460981F2-B782-4FAC-8C8A-5ABB1EDEFB42

P2093

Q38516135-4CE3678E-A701-4713-A431-A0B060804585

Q38516135-73054149-FA8B-4E81-95C5-AB099773BEA7

Q38516135-89C2849F-82EA-43C6-8648-D8A1867819D1

Q38516135-914C7560-EE46-449E-AA95-082C7E1AB4AB

P2860

Q38516135-07935D2C-3236-46B4-B453-05F34E2A93CB

Q38516135-0DA3CAE3-C580-40A3-9EF7-8D34D4110E6D

Q38516135-0F80FA27-D854-4D1D-B99C-5824D22DAD6B

Q38516135-1C254956-4799-44F9-8CB0-5F0A8D94F225

Q38516135-2288E904-321B-4EFA-ADCA-41CCD9BFF812

Q38516135-2AD903F1-0F4C-49F1-883D-98EF8EFE600A

Q38516135-321C0A16-56CD-4D66-9623-1BD25FEBEF30

Q38516135-53592194-9016-4643-8D9D-90C6BE48823B

Q38516135-56998FEB-1990-47FD-86B4-3A0A983485AF

Q38516135-64C73ECC-16D3-4192-BE1A-49FC65ADA067

P304

Q38516135-A5002D5B-3290-45BA-B156-565B60C658C4

P31

Q38516135-BA9FCAB4-BE4F-4D09-BEC1-FCD683416935

P356

Q38516135-ECF9A625-C1D1-4C04-BEA6-6AF60F131BD0

P407

Q38516135-CA94F9FD-6A5A-4B55-B167-CFF0DC041C44

P433

Q38516135-374DB80C-0CF7-4A38-97D2-A867F48D8483

P478

Q38516135-AACDDFCA-FF50-4F5B-B6CC-2B44A6427A77

P577

Q38516135-8BEABF2B-2A12-43EF-9E6D-527108A92219

P698

Q38516135-B4D8E185-8482-4F04-8F48-FA2B4B809E30

P921

Q38516135-32D1EE0F-5D8C-4B17-9D46-686B499E41C1

P356

14740338.2015.1053868

P1433

Expert Opinion on Drug Safety

P1476

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

@en

P2093

Brian Lam

http://www.w3.org/2001/XMLSchema#string

Pegah Golabi

http://www.w3.org/2001/XMLSchema#string

Yousef Fazel

http://www.w3.org/2001/XMLSchema#string

Zobair Younossi

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Treatment of chronic hepatitis C--are interferons really necessary?

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.

NS5A inhibitors in the treatment of hepatitis C.

Drug interactions with new hepatitis C oral drugs.

P304

1317-1326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2015.1053868

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26043900

http://www.w3.org/2001/XMLSchema#string

P921